Maria D.
- Country
- Italy
- Department
- Pneumologia e Oncologia
Research Overview
- Safety Evaluation of CHF5993 pMDI Formulated with HFA-152a Versus HFA-134a in Moderate to Severe Asthma Patients
- Evaluation of Mepolizumab for Achieving Clinical Remission in Patients with Severe Asthma: A Prospective, Real-World Interventional Study
- Efficacy and Safety Evaluation of Subcutaneous Amlitelimab in Adults with Moderate-to-Severe Asthma: A Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 30 of 210 partner sites.
Specializations
Respiratory Medicine
This investigator specializes in the management of severe and inadequately controlled asthma, with particular focus on innovative therapeutic approaches using combination inhaler treatments.
- Advanced inhaler therapies
- Bronchodilator combinations
- Treatment-resistant asthma
Their research encompasses the evaluation of various inhaler formulations including budesonide, glycopyrronium, and formoterol combinations.
Clinical Innovation
The investigator conducts research on novel propellant technologies in respiratory medicine, evaluating alternative delivery systems for asthma medications.
- Pressurized metered dose inhalers
- Environmental impact assessment
- Safety evaluation studies
Their work includes comparative studies of different propellant systems in asthma medication delivery devices.
Therapeutic Development
Expertise extends to the investigation of biological therapies for asthma treatment, including research on innovative compounds like amlitelimab and mepolizumab.
- Long-term efficacy studies
- Clinical remission assessment
- Dose optimization research
The investigator focuses on evaluating both immediate and sustained therapeutic responses in asthma management.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.